Výsledky vyhledávání - "Daniel Stellato"

Akademický článek

Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer

Autor: Daniel Stellato, Marroon Thabane, Caitlin Eichten, Thomas E. Delea

Publikováno v: Current Oncology, Vol 28, Iss 1, Pp 491-508 (2021)

(1) Background: Past research suggests that patients with advanced breast cancer prefer treatments with improved clinical outcomes and lower risk of side effects. Evidence on preferences of Canadian patients and physicians for treatments for advanced

Externí odkaz: https://doaj.org/article/110b00e47cb340c09b95969d0c3fef56

Zobrazit plný text záznamu

Preferences of Canadian Patients and Physicians for Adjuvant Treatments for Melanoma

Autor: M. Thabane, Thomas E. Delea, Daniel Stellato, Caitlin Eichten

Publikováno v: Current Oncology
Volume 26
Issue 6
Pages 5085-765

Past research suggests that patients with early- and late-stage melanoma will endure adverse events and inconvenient treatment regimens for improved survival. Evidence about the preferences of Canadian patients and physicians for novel adjuvant treat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82b9ada226e07d3c11034394e8725c55
https://doi.org/10.3747/co.26.5085

Zobrazit plný text záznamu

Budget Impact of Dabrafenib and Trametinib in Combination as Adjuvant Treatment of BRAF V600E/K Mutation-Positive Melanoma from a U.S. Commercial Payer Perspective

Autor: Dinesh Mishra, Margaret E. Gerbasi, Roy Koruth, Sameer R. Ghate, Briana Ndife, Aaron Moynahan, Daniel Stellato, P Gunda, Thomas E. Delea

Publikováno v: Journal of Managed Care & Specialty Pharmacy. 25:1227-1237

Before the approval of dabrafenib and trametinib in combination, there were no approved therapies in the adjuvant setting that target the RAS/RAF/MEK/ERK pathway.To evaluate the budget impact of dabrafenib and trametinib in combination for adjuvant t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5112ed55d08cc354d994682606656a84
https://doi.org/10.18553/jmcp.2019.25.11.1227

Zobrazit plný text záznamu

Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective

Autor: Margaret E. Gerbasi, Briana Ndife, Thomas E. Delea, Aaron Moynahan, Roy Koruth, Daniel Stellato, P Gunda, Dinesh Mishra, Sameer R. Ghate

Publikováno v: Journal of Medical Economics. 22:1243-1252

Objective The COMBI-AD trial demonstrated the efficacy and safety of dabrafenib and trametinib in combination versus placebo as adjuvant treatment of patients with BRAF V600E/K mutation-positive resected Stage IIIA (lymph node metastasis >1 mm), IIIB

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::115bb8bd22b0e71a8756ed2a68b53d3a
https://doi.org/10.1080/13696998.2019.1635487

Zobrazit plný text záznamu

Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective

Autor: Jinhee Park, M. Thabane, Daniel Stellato, David Chandiwana, Thomas E. Delea

Publikováno v: PharmacoEconomics. 39(9)

The MONALEESA-3 trial demonstrated the efficacy and safety of ribociclib plus fulvestrant versus placebo plus fulvestrant for patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cbd402127f77fcca7408662f2b9024e
https://pubmed.ncbi.nlm.nih.gov/34105083

Zobrazit plný text záznamu

Survival outcomes in patients with chronic phase chronic myeloid leukemia (CP-CML) receiving third- or subsequent line (3L) treatment prior to the availability of ponatinib

Autor: Shaina Hastings, Lisa J. McGarry, Hui Huang, Thomas E. Delea, Daniel Stellato

Publikováno v: Journal of Clinical Oncology. 35:e18553-e18553

e18553 Background: PACE was a phase 2 single-arm trial of ponatinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in 449 highly-refractory patients with CML or Philadelphia-chromosome positive (Ph+) acute lymphocytic leukemia (ALL) or who had th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::86d2065d7d98fb11a0cdaa24f3ddc0ab
https://doi.org/10.1200/jco.2017.35.15_suppl.e18553

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání